Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/46380
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ricciardelli, C. | - |
dc.contributor.author | Jackson, M. | - |
dc.contributor.author | Choong, C. | - |
dc.contributor.author | Stahl, J. | - |
dc.contributor.author | Marshall, V. | - |
dc.contributor.author | Horsfall, D. | - |
dc.contributor.author | Tilley, W. | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | The Prostate, 2008; 68(8):830-838 | - |
dc.identifier.issn | 0270-4137 | - |
dc.identifier.issn | 1097-0045 | - |
dc.identifier.uri | http://hdl.handle.net/2440/46380 | - |
dc.description.abstract | <h4>Background</h4>In this study, we investigated the expression of HER-2/neu and AR in clinically organ-confined prostate cancer to determine whether alterations in these signaling pathways contribute to the development of metastatic disease.<h4>Methods</h4>HER-2/neu and AR immunoreactivity were evaluated in archived prostatic tissues obtained from 53 men with clinically organ-confined disease who underwent radical prostatectomy. Associations between AR and HER-2/neu immunostaining and disease outcome were determined.<h4>Results</h4>Seventy percent (37/53) of tumors exhibited high levels of HER-2/neu immunostaining and 68% (36/53) of tumors had elevated AR levels. Patients with high levels of both HER-2/neu and AR had the highest rate of PSA failure (56%, 15/27) compared with no PSA failures amongst seven patients with low levels of both HER-2/neu and AR (log rank statistic 7.69, P = 0.021). Concurrent high levels of HER-2/neu and AR expression were significantly associated with high pathological stage (P = 0.027) and development of metastatic disease (P = 0.022).<h4>Conclusions</h4>These findings support the notion that both the HER-2/neu and AR signaling pathways may contribute to development of metastatic disease. The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways. | - |
dc.description.statementofresponsibility | Ricciardelli C, Jackson M.W, Choong C.S, Stah J, Marshall V.R, Horsfall D.J and Tilley W.D. | - |
dc.language.iso | en | - |
dc.publisher | Wiley-Liss | - |
dc.source.uri | http://dx.doi.org/10.1002/pros.20747 | - |
dc.subject | Humans | - |
dc.subject | Prostatic Neoplasms | - |
dc.subject | Neoplasm Metastasis | - |
dc.subject | Neoplasm Recurrence, Local | - |
dc.subject | Prostate-Specific Antigen | - |
dc.subject | Receptor, erbB-2 | - |
dc.subject | Receptors, Androgen | - |
dc.subject | Prostatectomy | - |
dc.subject | Immunohistochemistry | - |
dc.subject | Aged | - |
dc.subject | Middle Aged | - |
dc.subject | Male | - |
dc.title | Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1002/pros.20747 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ricciardelli, C. [0000-0001-7415-1854] | - |
dc.identifier.orcid | Tilley, W. [0000-0003-1893-2626] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.